


Eplerenone

Chemical Properties

| | |
|-------------------|---|
| CAS No. : | 107724-20-9 |
| Formula: | C ₂₄ H ₃₀ O ₆ |
| Molecular Weight: | 414.49 |
| Storage: | Powder: -20°C for 3 years In solvent: -80°C for 1 year Actual storage temperature shall be subject to the COA. |



Biological Description

| | |
|---------------|--|
| Description | Eplerenone (CGP 30083) is an aldosterone receptor antagonist and potassium-sparing diuretic used in the therapy of hypertension. Eplerenone therapy has been associated with transient elevations in serum aminotransferase levels, but has yet to be linked to cases of clinically apparent drug induced liver disease. |
| Targets(IC50) | Glucocorticoid Receptor, Endogenous Metabolite |
| In vitro | Eplerenone increases total vascular and luminal areas in swine without affecting the endothelial area. In canine models, it significantly reduces left ventricular end-diastolic wall stress. Eplerenone attenuates the rise in pulse pressure due to aldosterone (Aldo) in rats, normalizing the wall stress curve, mean cross-sectional area, and EIIA fibronectin levels in Aldo-salt hypertensive rats. The compound upregulates diminished endothelial nitric oxide synthase mRNA in Dahl salt-sensitive hypertensive (DS) rats, markedly improving glomerulosclerosis and proteinuria. In mice, daily administration of 200 mg/kg of Eplerenone significantly lowers systolic and diastolic blood pressures compared to controls and increases serum phosphatase activity. |

Solubility Information

| | |
|---------------------|---|
| Solubility | DMSO: 7.14 mg/mL (17.23 mM), Sonication is recommended. (< 1 mg/ml refers to the product slightly soluble or insoluble) |
| In vivo Formulation | 10% DMSO+40% PEG300+5% Tween 80+45% Saline: 1 mg/mL (2.41 mM), Sonication is recommended. <i>Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. The formulation provided above is for reference purposes only. In vivo formulations may vary and should be modified based on specific experimental conditions.</i> |

Preparing Stock Solutions

| | 1mg | 5mg | 10mg |
|-------|-----------|-----------|-----------|
| 1 mM | 2.4126 mL | 12.063 mL | 24.126 mL |
| 5 mM | 0.4825 mL | 2.4126 mL | 4.8252 mL |
| 10 mM | 0.2413 mL | 1.2063 mL | 2.4126 mL |
| 50 mM | 0.0483 mL | 0.2413 mL | 0.4825 mL |

Please select the appropriate solvent to prepare the stock solution, according to the solubility of the product in different solvents. Please use it as soon as possible.

Note: The dilution table applies only to solid products. For liquid products, please calculate the stock solution based on the stated concentration and/or density.

Reference

- Kobayashi N, et al. Hypertension, 2005, 45(4), 538-544.
- Keidar S, et al. J Cardiovasc Pharmacol, 2003, 41(6), 955-963.
- Ward MR, et al. Circulation, 2001, 104(4), 467-472.
- Suzuki G, et al. Circulation, 2002, 106(23), 2967-2972.
- Lacolley P, et al. Circulation, 2002, 106(22), 2848-2853.

Inhibitor · Natural Compounds · Compound Libraries · Recombinant Proteins

This product is for Research Use Only · Not for Human or Veterinary or Therapeutic Use

Tel: 781-999-4286 E_mail: info@targetmol.com Address: 34 Washington Street, Wellesley Hills, MA 02481